Skip to main content
Sign In

University of Colorado Denver

​​​​​​​​​ ​
 

Robert I. Scheinman, PhD

Associate Research Professor of Biochemistry, Department of Pharmaceutical Sciences


Mailing address:

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Mail Stop C238
12850 E. Montview Blvd. V20-4130
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4130

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4460D(N)/4470

Contact:

Affiliations:

  • Member, University of Colorado Cancer Center
  • Member, Pharmacology Graduate Program
  • Member, Biomedical Sciences Graduate Program

Training and Education:

  • BS, Massachusetts Institute of Technology (Biology)
  • PhD, University of Washington, Seattle (Pharmacology)

Clinical / Research Interests:

My research focus concerns the general study of inflammation in the context of disease with a more specific focus on factors that modify transcriptional regulation. The three major disease states in which I work include arthritis, diabetes, and cancer. Inflammation represents the body’s response to danger which may involve infection, acute tissue damage (trauma), or chronic tissue damage (inflammatory diseases). Cells such as macrophages and dendritic cells play complex roles in this process; first acting as soldier and then as healer. The process by which this occurs involves the genomic reorganization of the cell and is poorly understood. Other cells of the body contribute signals which strongly affect this process in a manner that is intensely situational. Within this complexity, we are focused on both understanding the signaling circuitry that comes into play and the identification of targets for therapeutic intervention. Additionally, I have formed a close collaboration with Uday Kompella and together we are generating nano-formulations which deliver transcriptional modulators to diseased tissues. We are currently focused on the delivery of siRNA therapeutics to specific cell types via the molecular programming of these formulations.

Teaching:

  • Professional Program: Biochemistry, Pharmacology

Representative Publications:

  • Williams-Skipp, C. Raman, T., Valuck, R.J., Watkins, H., Palmer, B., and Scheinman, RI. (2009) Unmasking of a Protective TNFR1 Mediated Signal in the Collagen Arthritis Model. Arthritis and Rheumatism in press. Featured Cover Article.
  •  Scheinman, RI, Trivedi, R, Vermillion, S, Kompella, U (2011) RGD-Functionalized STAT1 siRNA Nanoparticles Regress Rheumatoid Arthritis in a Mouse Model. Nanomedicine (London) 6(10):1669-1682
  • Baid, R, Scheinman, RI, Shinohara, T., Singh, DP, Kompella UB. (2011) LEDGF1-326 Decreases P23H and Wild Type Rhodopsin Aggregates and P23H Rhodopsin Mediated Cell Damage in Human Retinal Pigment Epithelial Cells. PLoSOne 6(9):e24616
  • Thakur, A, Scheinman, RI, Rao, V, and Kompella UB. (2011) Pazopanib, a multitargeted tyrosine kinase inhibitor, reduced diabetic retinal vascular leukostasis and leakage. Microvasc Res. 82(3):346-50.
  • Scheinman, RI. (2012) Pleiotropic targets: the problem of shared signaling circuitry in rheumatoid disease progression and protection. Future Med Chem 4(6):75.
  • Scheinman, RI. (2013) NF-κB and Rheumatoid Arthritis: Will Understanding Genetic Risk Lead to a Therapeutic Reward? Forum on Immunopathological Diseases and Therapeutics 4(2):93-110.

Keywords:

NF-κB, Arthritis, Diabetes, Inflammation, TNF, Signal transduction, Autoimmunity, Negative selection, Thymic selection, AIRE, Autoimmune Regulator